Furthermore, the limited benefit of Eve, particularly in hormone receptor-negative BC, is counterbalanced by a high toxicity due to off-target actions of the drug, particularly grade 3–4 neutropenia and stomatitis [1,2]. The gene discussed is NR4A1; the disease is Decreased total neutrophil count.